Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lymphoma 7Lymphoma, Follicular 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, Mantle-Cell 3Recurrence 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-Cell Malignancies 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × parsaclisib × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡